Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
18F-PMPBB3 (APN-1607) PET imaging
Hospital Authority, Hong Kong
Tau Distributions in Patients With Tauopathy Using APN-1607 PET Scan
1 trial -
18F-PSMA-1007
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
1 trial -
25% Carbohydrate solution (CHO drinking)
Hospital Authority, Hong Kong
Type2diabetes
1 trial -
2L PEG
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Bowel Preparation Scale
1 trial -
5-gene classification model
Hospital Authority, Hong Kong
ABO Blood Type Incompatible Kidney Transplantation
1 trial -
68Ga-DOTA-NT-20.3
The First People's Hospital of Lianyungang
Pancreatic Ductal Adenocarcinoma
1 trial -
68Ga-Her2-affibody
The First People's Hospital of Lianyungang
Neoplasms
1 trial -
68Ga-pentixafor
Zhongnan Hospital
CXCR4
1 trial -
75 mg acetylsalicylic acid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Preeclampsia
1 trial -
89Zr-KN035
The First People's Hospital of Lianyungang
Solid Tumor, Adult
1 trial -
99mTc-4BOH SPECT myocardial perfusion imaging
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Artery Disease
1 trial -
99mTc-H7ND SPECT/CT imaging performed
The First People's Hospital of Lianyungang
NSCLC
1 trial -
A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).
The First People's Hospital of Lianyungang
Neuromuscular Blockade
1 trial -
A single dose of liposomal bupivacaine is administered at the conclusion of surgery without adjunctive analgesics, followed by a supplemental dose 72 hours postoperatively.
The First People's Hospital of Lianyungang
Anal Fistula
1 trial -
A+ HA(tm)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Knee Osteoarthritis
2 trials -
AIM-CHD Mobile Health Intervention
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Secondary Prevention of Coronary Heart Disease
1 trial -
AREG-TRIGGER
Hospital Authority, Hong Kong
PCOS
1 trial -
ASC09/ritonavir group
The First People's Hospital of Lianyungang
2019-nCoV
1 trial -
ATRA+Venetoclax+Azacitidine
The First People's Hospital of Lianyungang
AML, Adult
1 trial -
Abbreviated non-contrast MRI of the liver
Hospital Authority, Hong Kong
Hepatocellular Carcinoma
1 trial -
Acalabrutinib
The First People's Hospital of Lianyungang
Chronic Lymphocytic Leukemia
1 trial -
Accurate Prediction Artificial Intelligence Models
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Acetaminophen
Hospital Authority, Hong Kong
Elbow Fracture
1 trial -
Adjustment of Antiplatelet Drugs
The First People's Hospital of Lianyungang
Intracranial Aneurysm
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources